Eribulin is named as an intervention in 23 current clinical trials in our China, USA, UK and India registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is BioNTech SE (2). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 4 |
| Triple Negative Breast Cancer | 4 |
| Metastatic Breast Cancer | 2 |
| Breast Neoplasms | 2 |
| Soft Tissue Sarcoma (STS) | 2 |
| Breast Cancer, Metastatic | 1 |
| Locally Advanced Breast Cancer | 1 |
| Metastatic Triple Negative Breast Cancers | 1 |
| Metastatic HER2-positive Breast Cancer | 1 |
| Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | 1 |
| HER2-positive Breast Cancer | 1 |
| HER2-positive Gastric Cancer | 1 |
| HER2 Positive Solid Tumors | 1 |
| HER2 Amplification | 1 |
| Endometrial Neoplasms | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Platinum-resistant Ovarian Cancer (PROC) | 1 |
| Sarcoma,Soft Tissue | 1 |
| HER2-negative Breast Cancer | 1 |
| Advanced Breast Cancer | 1 |
| Inoperable Locally Advanced HER2-Negative Breast Cancer | 1 |
| Metastatic HER2-Negative Breast Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| Breast Cancer Stage IV | 1 |
| Triple -Negative Breast Cancer | 1 |
| Triple-Negative Breast Cancer | 1 |
| Locally Advanced or Metastatic Breast Cancer | 1 |
| HR+HER2- Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| BioNTech SE | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 |
| Hoffmann-La Roche | 1 |
| ALX Oncology Inc. | 1 |
| AstraZeneca | 1 |
| Jazz Pharmaceuticals | 1 |
| Daiichi Sankyo | 1 |
| Criterium, Inc. | 1 |
| Enliven Therapeutics | 1 |
| Advenchen Pharmaceuticals, LLC. | 1 |
| GI Innovation, Inc. | 1 |
| Intensity Therapeutics, Inc. | 1 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 |
+ 6 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 6 |
| Clinical trials in USA | 12 | 6 |
| Clinical trials in UK | 7 | 4 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
23 current trials in our China, USA, UK and India registers name Eribulin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 23 trials are recruiting: 6 with sites in China, 6 with sites in USA and 4 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BioNTech SE (2), Sichuan Baili Pharmaceutical Co., Ltd (2), Hoffmann-La Roche (1) and ALX Oncology Inc (1), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Eribulin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Eribulin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Eribulin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.